Suppr超能文献

肿瘤坏死因子和DNA拓扑异构酶II抑制剂在人类卵巢癌中的作用——在化疗中的潜在作用

Tumor-necrosis-factor and DNA topoisomerase-ii inhibitors in human ovarian-cancer - potential role in chemotherapy.

作者信息

Aluigi M, Debernardis D, Cimoli G, Ottoboni C, Parodi S, Russo P

机构信息

IST NAZL RIC CANC,DEPT CHEM CARCINOGENESIS,I-16132 GENOA,ITALY.

出版信息

Int J Oncol. 1995 Sep;7(3):461-7.

Abstract

Seven ovarian and one cervical human cancer cell lines were examined far their sensitivity or resistance to tumor necrosis factor, to three topoisomerase II inhibitors and to cisplatin. Only one line exhibited the multidrug-resistance phenotype and another one an 'atypical'-MDR phenotype. The combination of TNF and topoisomerase-II inhibitors produced enhanced cytotoxicity and overcame the MDR and the atypical resistance. No potentiation of cisplatin cytotoxicity was observed. These findings suggest that TNF enhances the activity of DNA topoisomerase II both in TNF resistant and sensitive cells.

摘要

检测了七种卵巢癌细胞系和一种宫颈癌细胞系对肿瘤坏死因子、三种拓扑异构酶II抑制剂和顺铂的敏感性或抗性。只有一种细胞系表现出多药耐药表型,另一种表现出“非典型”多药耐药表型。肿瘤坏死因子与拓扑异构酶II抑制剂联合使用可增强细胞毒性,并克服多药耐药和非典型耐药。未观察到顺铂细胞毒性的增强。这些发现表明,肿瘤坏死因子在肿瘤坏死因子耐药和敏感细胞中均能增强DNA拓扑异构酶II的活性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验